Title : Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review.

Pub. Date : 2018 Dec

PMID : 30791790






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 For genotype 1, the highest number of ICER comparison corresponds to sofosbuvir (SOF) triple therapy and SOF-based combinations which reported a cost per QALY systematically ranging from negative to lower than US$100,000 when compared with no treatment or dual therapy or Simeprevir triple therapy. Sofosbuvir cAMP responsive element modulator Homo sapiens
2 For genotype 1, the highest number of ICER comparison corresponds to sofosbuvir (SOF) triple therapy and SOF-based combinations which reported a cost per QALY systematically ranging from negative to lower than US$100,000 when compared with no treatment or dual therapy or Simeprevir triple therapy. Sofosbuvir cAMP responsive element modulator Homo sapiens